Current Approaches and Emerging Directions in HER2-resistant Breast Cancer
Human epidermal growth factor receptor-2 (HER2) is overexpressed in up to 30% of breast cancers; HER2 overexpression is indicative of poor prognosis. Trastuzumab, an anti-HER2 monoclonal antibody, has led to improved outcomes in patients with HER2-positive breast cancer, including improved overall s...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2014-01-01
|
| Series: | Breast Cancer: Basic and Clinical Research |
| Online Access: | https://doi.org/10.4137/BCBCR.S9453 |
| _version_ | 1811335251784368128 |
|---|---|
| author | Adam M. Brufsky |
| author_facet | Adam M. Brufsky |
| author_sort | Adam M. Brufsky |
| collection | DOAJ |
| description | Human epidermal growth factor receptor-2 (HER2) is overexpressed in up to 30% of breast cancers; HER2 overexpression is indicative of poor prognosis. Trastuzumab, an anti-HER2 monoclonal antibody, has led to improved outcomes in patients with HER2-positive breast cancer, including improved overall survival in adjuvant and first-line settings. However, a large proportion of patients with breast cancer have intrinsic resistance to HER2-targeted therapies, and nearly all become resistant to therapy after initial response. Elucidation of underlying mechanisms contributing to HER2 resistance has led to development of novel therapeutic strategies, including those targeting HER2 and downstream pathways, heat shock protein 90, telomerase, and vascular endothelial growth factor inhibitors. Numerous clinical trials are ongoing or completed, including phase 3 data for the mammalian target of rapamycin inhibitor everolimus in patients with HER2-resistant breast cancer. This review considers the molecular mechanisms associated with HER2 resistance and evaluates the evidence for use of evolving strategies in patients with HER2-resistant breast cancer. |
| first_indexed | 2024-04-13T17:21:27Z |
| format | Article |
| id | doaj.art-5bbaf93c55fb44e0861729db5240a7fe |
| institution | Directory Open Access Journal |
| issn | 1178-2234 |
| language | English |
| last_indexed | 2024-04-13T17:21:27Z |
| publishDate | 2014-01-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Breast Cancer: Basic and Clinical Research |
| spelling | doaj.art-5bbaf93c55fb44e0861729db5240a7fe2022-12-22T02:37:58ZengSAGE PublishingBreast Cancer: Basic and Clinical Research1178-22342014-01-01810.4137/BCBCR.S9453Current Approaches and Emerging Directions in HER2-resistant Breast CancerAdam M. Brufsky0Comprehensive Breast Cancer Center, University of Pittsburgh School of Medicine, Magee-Women's Hospital, Pittsburgh, PA, USA.Human epidermal growth factor receptor-2 (HER2) is overexpressed in up to 30% of breast cancers; HER2 overexpression is indicative of poor prognosis. Trastuzumab, an anti-HER2 monoclonal antibody, has led to improved outcomes in patients with HER2-positive breast cancer, including improved overall survival in adjuvant and first-line settings. However, a large proportion of patients with breast cancer have intrinsic resistance to HER2-targeted therapies, and nearly all become resistant to therapy after initial response. Elucidation of underlying mechanisms contributing to HER2 resistance has led to development of novel therapeutic strategies, including those targeting HER2 and downstream pathways, heat shock protein 90, telomerase, and vascular endothelial growth factor inhibitors. Numerous clinical trials are ongoing or completed, including phase 3 data for the mammalian target of rapamycin inhibitor everolimus in patients with HER2-resistant breast cancer. This review considers the molecular mechanisms associated with HER2 resistance and evaluates the evidence for use of evolving strategies in patients with HER2-resistant breast cancer.https://doi.org/10.4137/BCBCR.S9453 |
| spellingShingle | Adam M. Brufsky Current Approaches and Emerging Directions in HER2-resistant Breast Cancer Breast Cancer: Basic and Clinical Research |
| title | Current Approaches and Emerging Directions in HER2-resistant Breast Cancer |
| title_full | Current Approaches and Emerging Directions in HER2-resistant Breast Cancer |
| title_fullStr | Current Approaches and Emerging Directions in HER2-resistant Breast Cancer |
| title_full_unstemmed | Current Approaches and Emerging Directions in HER2-resistant Breast Cancer |
| title_short | Current Approaches and Emerging Directions in HER2-resistant Breast Cancer |
| title_sort | current approaches and emerging directions in her2 resistant breast cancer |
| url | https://doi.org/10.4137/BCBCR.S9453 |
| work_keys_str_mv | AT adammbrufsky currentapproachesandemergingdirectionsinher2resistantbreastcancer |